Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - NETs and endocrine tumours

1098O - Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)

Date

21 Sep 2021

Session

Proffered Paper session - NETs and endocrine tumours

Presenters

Maria Carmen Riesco-Martinez

Citation

Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016/annonc/annonc678

Authors

M.C. Riesco-Martinez1, J. Capdevila2, V. Alonso3, P. Jimenez-Fonseca4, A. Teule5, E. Grande6, I. Sevilla7, M. Benavent Viñuales8, T. Alonso-Gordoa9, A. Custodio10, J. Hernando2, E. Polo3, O.A. Castillo Trujillo4, R. Garcia-Carbonero11

Author affiliations

  • 1 Medical Oncology Department, Hospital Universitario 12 Octubre, Imas12, UCM, 28041 - Madrid/ES
  • 2 Medical Oncology Department, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), 8035 - Barcelona/ES
  • 3 Medical Oncology Department, Instituto Aragones de Investigacion Sanitaria, Hospital Universitario Miguel Servet, Zaragoza/ES
  • 4 Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo/ES
  • 5 Medical Oncology Department, Institut Català d´Oncologia (ICO) - IDIBELL, L`Hospitalet de Llobregat/ES
  • 6 Medical Oncology Department, MD Anderson Cancer Center Madrid, 28033 - Madrid/ES
  • 7 Medical Oncology Department, Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga/ES
  • 8 Medical Oncology Department, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville/ES
  • 9 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 10 Medical Oncology Department, Hospital Universitario La Paz, Madrid/ES
  • 11 Medical Oncology Department, Hospital Universitario 12 Octubre, Imas12, UCM, Madrid/ES
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1098O

Background

Grade 3 (G3) NENs encompass a heterogeneous group of tumors with aggressive behaviour and poor survival. Standard front-line platinum-based chemotherapy (CT) has limited efficacy, with an ORR of 31%, a median PFS of 4-5 m and a median OS of 11 m. G3 NENs are associated with a high mutational burden and PD-L1 expression that might lead to a favorable response to immunotherapy (IT). The aim of this study is to assess the safety and potential synergy of the combination of CT plus IT in patients with advanced CT-naïve G3 NENs.

Methods

NICE-NEC is a non-randomized, open-label, phase II trial that recruited patients (pts) with histologically confirmed metastatic or unresectable G3 NENs of GEP/UK origin, treatment-naïve and ECOG 0-2 across 12 centers belonging to the Spanish Taskforce of Neuroendocrine Tumors (GETNE). Pts received Nivolumab 360 mg iv d1/ Carboplatin AUC 5 iv d1/ Etoposide 100 mg/m2 d1-3 every 3 weeks (up to 6 cycles) followed by Nivolumab 480 mg every 4 weeks (up to 24 m) as maintenance tx. Primary endpoint was 12mOS rate. Secondary endpoints include ORR by RECIST 1.1, PFS and safety.

Results

From 2019-2021, 38 pts were enrolled. Median age was 61y, 68% male, 29% ECOG 0, 53% poorly differentiated and 66% Ki67 >55%. 81.6% were GEP; pancreas 37%, stomach 16% and colorectum 16% were the most common sites. 74% had ≥2 metastatic organs involved. With a median follow up of 6 m, disease control rate (DCR) was 84% including an ORR of 50% (47% PR; 3% CR). Median and 6m-PFS rate were 5.7 m (95%CI: 5.1-7.8) and 39% (95%CI: 25-62), respectively. ≥G3 AEs were reported in 61% pts. Most frequent toxicities were hematological: neutropenia (53%), febrile neutropenia (10%) and anemia (11%).

Conclusions

Preliminary results show promising activity of adding Nivolumab to CT as first-line therapy for G3 NENs, with DCR of 84% and greater ORR than benchmark studies. Nivolumab did not significantly increase the toxicity profile of standard CT. Final survival results require further follow-up and translational studies are ongoing.

Clinical trial identification

EudraCT 2019-001546-18; NCT03980925.

Editorial acknowledgement

We acknowledge MFAR Clinical Research staff for their assistance in the development of this abstract.

Legal entity responsible for the study

Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE).

Funding

Bristol Myers Squibb (BMS).

Disclosure

M.C. Riesco-Martinez: Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Merk; Financial Interests, Personal, Advisory Role: AAA; Financial Interests, Institutional, Research Grant, Grant for investigator-initiated study.: BMS; Financial Interests, Institutional, Research Grant, Grant for investigator-initiated study.: MSD. J. Capdevila: Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Amgen; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Bayer; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Eisai; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: AAA; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Ipsen; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Pfizer; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Merck; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Sanofi; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Novartis; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Lilly; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: ITM; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Hudchinson Pharma; Financial Interests, Personal, Other, Scientific consultancy role - Participation in speaker´s bureau: Exelixis; Financial Interests, Personal, Other, Receipt of grants / research supports: Eisai; Financial Interests, Personal, Other, Receipt of grants / research supports: AstraZeneca; Financial Interests, Personal, Other, Receipt of grants / research supports: AAA; Financial Interests, Personal, Other, Receipt of grants / research supports: Ipsen; Financial Interests, Personal, Other, Receipt of grants / research supports: Pfizer; Financial Interests, Personal, Other, Receipt of grants / research supports: Novartis; Non-Financial Interests, Personal, Member, Chair of GETNE: GETNE; Non-Financial Interests, Personal, Member, Advisory member: ENETS. P. Jimenez-Fonseca: Financial Interests, Personal, Advisory Role: Bristol; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Mylan; Financial Interests, Personal, Advisory Role: Baxter; Financial Interests, Personal, Invited Speaker: HRA Pharma; Financial Interests, Personal, Invited Speaker: LeoPharma; Financial Interests, Personal, Invited Speaker: Rovi; Financial Interests, Personal, Invited Speaker: Sanofi. A. Teule: Financial Interests, Personal, Other, Speaking, writing, public presentations, advisory service, travel grants: Novartis; Financial Interests, Personal, Other, Speaking, writing, public presentations, advisory service, travel grants: IPSEN; Financial Interests, Personal, Other, Speaking, writing, public presentations, advisory service, travel grants: AAA; Financial Interests, Personal, Other, Speaking, writing, public presentations, advisory service, travel grants: Pfizer; Financial Interests, Personal, Other, Speaking, writing, public presentations, advisory service, travel grants: AstraZeneca. E. Grande: Financial Interests, Personal, Invited Speaker: Adacap; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Board: Caris Life Sciences; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Eusa Pharma; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Merk kGa; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: ONCODNA (Biosequence); Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Sanofi-Genzyme; Non-Financial Interests, Institutional, Research Grant: Astellas; Non-Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Institutional, Other, Coordinating PI: Ipsen; Non-Financial Interests, Institutional, Research Grant: Lexicon; Non-Financial Interests, Institutional, Research Grant: MTEM/Threshold; Non-Financial Interests, Institutional, Research Grant: Nanostring technologies; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Roche; Non-Financial Interests, Personal, Advisory Board: ENETS. I. Sevilla: Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Syrtex; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: AAA. M. Benavent Viñuales: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Novartis. T. Alonso-Gordoa: Financial Interests, Personal, Other, Speaker, consultancy or advisory role: Ipsen; Financial Interests, Personal, Other, Speaker, consultancy or advisory role: Pfizer; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: Janssen-Cilag; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Other, Speaker, consultancy or advisory role: BMS; Financial Interests, Personal, Other, Speaker, consultancy or advisory role: Eisai; Financial Interests, Institutional, Other, Clinical Trial: Roche; Financial Interests, Institutional, Other, Clinical Trial: AstraZeneca; Financial Interests, Institutional, Other, Clinical Trial: BMS; Financial Interests, Institutional, Other, Clinical Trial: MSD; Financial Interests, Institutional, Other, Clinical Trial: Eisai; Financial Interests, Institutional, Other, Clinical Trial: Pfizer; Financial Interests, Institutional, Other, Clinical Trial: Ipsen; Financial Interests, Institutional, Other, Clinical Trial: GSK-Novartis; Financial Interests, Institutional, Other, Clinical Trial: Clovis; Financial Interests, Institutional, Other, Clinical Trial: Nektar Therapeutics; Financial Interests, Institutional, Other, Clinical Trial: Janssen-Cilag; Financial Interests, Institutional, Other, Clinical Trial: Astellas; Financial Interests, Institutional, Other, Clinical Trial: Bayer; Non-Financial Interests, Personal, Project Lead: Pfizer; Non-Financial Interests, Personal, Project Lead: Roche; Non-Financial Interests, Personal, Project Lead: Ipsen; Non-Financial Interests, Personal, Member: Spanish Germ Cell Tumors Board; Non-Financial Interests, Personal, Advisory Role: SEOM. J. Hernando: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: AAA; Financial Interests, Personal, Invited Speaker: Angelini. R. Garcia-Carbonero: Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: AAA; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Advanz Pharma; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Bayer; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: BMS; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: HMP; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Ipsen; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Merck; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Midatech Pharma; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: MSD; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Novartis; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: PharmaMar; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Pfizer; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Pierre Fabre; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Roche; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Sanofi; Financial Interests, Personal, Other, Scientific Advice, Speakers Bureau, Honoraria: Servier; Financial Interests, Personal, Other, Financial support to investigator-initiated trials: Pfizer; Financial Interests, Personal, Other, Financial support to investigator-initiated trials: BMS; Financial Interests, Personal, Other, Financial support to investigator-initiated trials: MSD; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: ARMO Biosciences; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: AstraZeneca; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Pfizer; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Novartis; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Ipsen; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Roche; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Pharmacyclics; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Boston Biomedicals; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Merk; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: MSD; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Amgen; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Sanofi; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Bayer; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Bristol-Myers-Squibb; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Boehringer; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Sysmex; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Gilead Sciences; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Servier; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Adacap; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: VCN; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: Lilly; Financial Interests, Institutional, Other, Institutional support for the conduct of clinical trials or for molecular diagnostic platforms: PharmaMar; Non-Financial Interests, Personal, Member, Member of the Executive Committee: GETNE; Non-Financial Interests, Personal, Member, Member of the Executive Committee: ENETS; Non-Financial Interests, Personal, Principal Investigator: Pfizer; Non-Financial Interests, Personal, Principal Investigator: BMS; Non-Financial Interests, Personal, Member: EORTC; Non-Financial Interests, Personal, Member: ASCO; Non-Financial Interests, Personal, Member: ESMO; Non-Financial Interests, Personal, Member: SEOM; Non-Financial Interests, Personal, Member: TTD; Non-Financial Interests, Personal, Member: GEMCAD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.